报价延迟最少15分钟:2025/09/13 22:58 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
16.8 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.46/--
|
|
企业价值
350.95M
|
| 资产负债 |
|
每股账面净值
不适用
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
--
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/09/13 22:58 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broadtherapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries. |
